High Velocity Nasal Insufflation Versus Continuous Positive Airway Pressure in COVID 19 Pneumonic Patients

Mansoura University

Status

Completed

Conditions

COVID-19 Pneumonia

Treatments

Device: High Velocity Nasal Insufflation

Device: Continuous Positive Airway Pressure

Study type

Interventional

Funder types

Other

Identifiers

NCT07213518

MS.21.08.1614

Details and patient eligibility

About

compare the efficacy of High-Velocity Nasal Insufflation (HVNI) versus Continuous Positive Airway Pressure (CPAP) in managing COVID 19 pneumonic patients with acute type 1 respiratory failure

Full description

A prospective randomized controlled trial was conducted on 108 patients with COVID 19 pneumonia with acute hypoxemic respiratory failure at Mansoura University Hospitals to compare the efficacy of High-Velocity Nasal Insufflation (HVNI) versus Continuous Positive Airway Pressure (CPAP) in managing COVID 19 pneumonic patients with acute type 1 respiratory failure, focusing on the need for invasive mechanical ventilation (IMV) and 28-day mortality. Patients were randomized into two equal groups: HVNI group and CPAP group. Baseline characteristics, respiratory parameters, and clinical outcomes were recorded.

Enrollment

108 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients aged above 18 years with COVID 19 pneumonia with acute type 1 respiratory failure were included.

Exclusion criteria

patients with hypercapnic respiratory failure.
patients with a disturbed level of consciousness and/or a high risk of aspiration
individuals with hypotension
patients requiring invasive mechanical ventilation.